Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

29 Jul 2015

Abstract excerpt

PURPOSE: Oncogenic mutations in the KRAS/PI3K/AKT pathway are one of the most frequent alterations in cancer. Although PI3K or AKT inhibitors show promising results in clinical trials, drug resistance frequently emerges. We previously revealed Wnt/β-catenin signaling hyperactivation as responsible for such resistance in colorectal cancer. Here we investigate Wnt-mediated resistance in patients treated with PI3K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to FOXO transcription factor regulation
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26224873
DOI: 10.1158/1078-0432.ccr-14-3081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal CancerPMID 26224873Read ↗

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.Semantic proximity Read ↗

The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.Semantic proximity Read ↗

APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cellsSemantic proximity Read ↗

Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.Semantic proximity Read ↗

Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)Semantic proximity Read ↗

Genomic alterations in the WNT/β-catenin pathway and resistance of colorectal cancer cells to pathway-targeting therapiesSemantic proximity Read ↗

Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status.Semantic proximity Read ↗

Tankyrase inhibition sensitizes cells to CDK4 blockade.Semantic proximity Read ↗

Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal TumorSemantic proximity Read ↗

Tankyrase inhibition sensitizes cells to CDK4 blockadeSemantic proximity Read ↗

The potential of targeting Wnt/β-catenin in colon cancerSemantic proximity Read ↗

Wnt signaling as a therapeutic target for cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.